Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

Eli Lilly releases data for a new weight-loss drug to tackle obesity : Shots - Health News There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Eli Lilly launched a new website to give patients suffering from obesity and diabetes access to telehealth providers. They can also get drugs delivered right to their home.

Eli Lilly is unveiling LillyDirect, a new digital healthcare platform for patients living with obesity, migraine and diabetes.LillyDirect offers disease management resources, including access to ...

Wednesday’s edition of Forbes Daily covers Labor Day gas prices, Mar-a-Lago's profitability, Kelce brothers ink a podcast deal, private equity in the NFL and more.

Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. The removal of ...

For Novo, the Morgan Stanley team expects obesity revenues of $11.7 billion in 2030, while Lilly’s tirzepatide—assuming it clinches an obesity green light—could make around $5.4 billion over ...